Sight Sciences' TearCare Treatment for Dry Eye Disease to Generate Cost Savings Versus Existing Prescribed Medications

MT Newswires Live

2024-12-20

Sight Sciences (SGHT) said late Thursday the increased adoption of its TearCare technology to treat patients with dry eye disease associated with meibomian gland dysfunction in the US is projected to yield "meaningful" cost savings based on the results of a budget impact analysis.

The analysis compared the financial impact of TearCare adoption with that of commonly prescribed dry eye medications, the company said.

A 20% increase in market share of TearCare compared to prescription dry eye medications would generate annual savings estimated at $36.87 per member in a hypothetical health plan covering one million people, the company added.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2492380344"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2492380344\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2492380344?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-12-20 06:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2492380344","market":"hk","top_or_hot":-1,"title":"Sight Sciences' TearCare Treatment for Dry Eye Disease to Generate Cost Savings Versus Existing Prescribed Medications","media":"MT Newswires Live","content":"<html><body><p> Sight Sciences (SGHT) said late Thursday the increased adoption of its TearCare technology to treat patients with dry eye disease associated with meibomian gland dysfunction in the US is projected to yield \"meaningful\" cost savings based on the results of a budget impact analysis.</p><p>The analysis compared the financial impact of TearCare adoption with that of commonly prescribed dry eye medications, the company said.</p><p>A 20% increase in market share of TearCare compared to prescription dry eye medications would generate annual savings estimated at $36.87 per member in a hypothetical health plan covering one million people, the company added.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sight Sciences' TearCare Treatment for Dry Eye Disease to Generate Cost Savings Versus Existing Prescribed Medications</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSight Sciences' TearCare Treatment for Dry Eye Disease to Generate Cost Savings Versus Existing Prescribed Medications\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2024-12-20 06:48</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Sight Sciences (SGHT) said late Thursday the increased adoption of its TearCare technology to treat patients with dry eye disease associated with meibomian gland dysfunction in the US is projected to yield \"meaningful\" cost savings based on the results of a budget impact analysis.</p><p>The analysis compared the financial impact of TearCare adoption with that of commonly prescribed dry eye medications, the company said.</p><p>A 20% increase in market share of TearCare compared to prescription dry eye medications would generate annual savings estimated at $36.87 per member in a hypothetical health plan covering one million people, the company added.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4539","symbol_name":"次新股","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2492380344","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2492380344","pubTimestamp":1734648481,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Sight Sciences  said late Thursday the increased adoption of its TearCare technology to treat patients with dry eye disease associated with meibomian gland dysfunction in the US is projected to yield \"meaningful\" cost savings based on the results of a budget impact analysis.The analysis compared the financial impact of TearCare adoption with that of commonly prescribed dry eye medications, the company said.A 20% increase in market share of TearCare compared to prescription dry eye medications would generate annual savings estimated at $36.87 per member in a hypothetical health plan covering one million people, the company added.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4539":"次新股","SGHT":"Sight Sciences, Inc.","BK4082":"医疗保健设备"},"translate_title":"与现有处方药相比，Sight Sciences针对干眼症的TearCare治疗可节省成本","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SGHT":1},"content_text":"Sight Sciences (SGHT) said late Thursday the increased adoption of its TearCare technology to treat patients with dry eye disease associated with meibomian gland dysfunction in the US is projected to yield \"meaningful\" cost savings based on the results of a budget impact analysis.The analysis compared the financial impact of TearCare adoption with that of commonly prescribed dry eye medications, the company said.A 20% increase in market share of TearCare compared to prescription dry eye medications would generate annual savings estimated at $36.87 per member in a hypothetical health plan covering one million people, the company added.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}